Key Drivers
- High profitability
- Strong liquidity
- Heavy reinvestment
AIAI Summary
Neurocrine has shifted from a high‑beta pipeline story to a cash‑generative commercial platform where valuation now hinges on successful conversion of a planned ~30% salesforce/+$150M SG&A expansion and preservation of realized pricing—so investors should hold/watch and only selectively accumulate after confirmatory clinical wins or clearer IRA/payer outcomes, while adverse INGREZZA trends or negative DOJ/IRA developments would warrant immediate reassessment.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High profitability
- •Strong liquidity
- •Heavy reinvestment
Neurocrine (NBIX) combines strong profitability, robust cash generation and low leverage with heavy R&D reinvestment and above‑average valuation multiples that price in growth. #HighR&D
Price Behavior
Key Price Behavior Insights:
- •Near-range bottom
- •Support tested
- •Momentum fading
Price action is mildly down over the last month, trading near the lower end of its range with support tested on 2026-03-12 and 2026-03-20 (slightly undercut), and resistance at the early‑March peak—watch for a defended bounce for a mean‑reversion entry or a close below support for continuation lower.
2026-03-20 close slightly undercut prior short-term support, signaling potential continuation risk
Sentiment & News
Key News Insights:
- •Conference roadshow
- •CTO promotion
- •Divergent ownership
Neurocrine saw heightened investor engagement via multiple conference presentations, an internal CTO promotion, and mixed institutional trading in early March 2026.
Continued investor outreach and executive strengthening should sustain attention but mixed institutional flows signal near-term stock volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings